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Role of the aclacinomycin A - doxorubicin association in reversal of
doxorubicin resistance in K562 tumour cells
J.-M. Millot, T.D.W. Rasoanaivo, H. Morjani & M. Manfait
Laboratoire de Spectroscopie Biomoleculaire, UFR de Pharmacie, 5I rue Cognacq-Jay, 51096 Reims Cedex, France.
Summary Acquired resistance to anthracyclines is characterised by a lower sensitivity to these agents,
associated with impaired accumulation of drug. We have examined the ability of aclacinomycin A (ACM)
associated with doxorubicin (DOX), to increase intranuclear DOX concentrations and, consequently, to
enhance cytotoxic effects against drug resistant cells in vitro. A recently developed microspectrofluorometric
technique is used to measure intranuclear DOX concentrations in sensitive and DOX-resistant K562 cells
treated with DOX and ACM. Fluorescence emission spectra are collected from a microvolume of single living
cell nuclei. From both DOX and ACM model fluorescence spectra (free, DNA-bound and metabolites), the
intranuclear spectral profile is analysed according to the amount of each component. This quantitative analysis
determines intranuclear DOX concentrations with an error of 10%. Non-cytotoxic doses of ACM, in
combination with DOX, increase cytotoxic activity of DOX against K562 resistant cells. When DOX-resistant
cells are exposed simultaneously to ACM and DOX, significant increases in intranuclear DOX concentrations
are found compared with the case of exposure to DOX alone. The measure of the intranuclear retention of
DOX shows that ACM partly blocks the DOX efflux in resistant cell nuclei, resulting in enhanced accumula-
tion of DOX. These data lead us to conclude that ACM-DOX association partly reverses the DOX resistance
at clinically achievable concentrations.
A major obstacle to successful use of anthracyclines and
other cytotoxic drugs in cancer chemotherapy is the develop-
ment of clinical drug resistance. Tumour cell modifications
(resulting in multidrug resistance) are characterised by a
complex phenotype of cross-resistance to antineoplasic agents
(Ling et al., 1983; Bradley et al., 1988). These are accom-
panied by gene amplification, a deficient accumulation of
drug, an enhanced drug efflux function and a build up of an
integral membrane glycoprotein with a molecular weight of
170,000-180,000 (P-glycoprotein) (Kartner et al., 1983). A
study with DNA transfectants (Riordan et al., 1985) has
demonstrated that the P-glycoprotein was intimately involved
in resistance and might be serving as an active efflux pump to
remove the drug from the cell. One way to overcome in vitro
resistance to anti-cancer drugs has been to use simul-
taneously calcium channel blockers (Tsuruo et al., 1983) or
calmodulin inhibitors (Ganapathi et al., 1984) together with
the anti-cancer drug. The mechanism of the resistance rever-
sal appears to be related to the inhibition of outward drug
transport which subsequently leads to increased intracellular
drug levels.
With the recent development of microspectrofluorometry,
we have studied fluorescence signals from microvolumes
within a single living cell (Ginot et al., 1984; Manfait et al.,
1987). DOX concentrations in nuclei of sensitive and DOX-
resistant K562 human leukaemia cell lines may thus be deter-
mined (Gigli et al., 1988). We have demonstrated the impor-
tance of the intranuclear concentration, since the cytotoxic
effect induced by DOX was dependent on the amount of
drug actually incorporated into the nucleus (Gigli et al.,
1989).
A previous report showed that high ACM levels
(10pgrml'), in combination with DOX or daunomycin, in-
creased the intracellular amount of the latter compounds
with concomitant increased cytotoxicity against resistant cells
(Tapiero et al., 1988). In this paper, we have extended these
inhibition growth studies with non-toxic doses of ACM
against DOX-resistant K562 cells in order to determine
which kind ofexposure with ACM and DOX, simultaneously
or sequentially, produced the most cytotoxicity. To explain
the reversal of resistance by ACM, we have measured the
DOX uptake directly into nuclei from living cells, using
microspectrofluorometry. Kinetics of DOX uptake and DOX
retention from sensitive and resistant cell nuclei have been
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studied with and without simultaneous ACM incubation. We
conclude that the increase of intranuclear amoants of DOX,
induced by ACM, depends on the DOX efflux inhibition in
resistant cell nuclei.
Materials and methods
Drugs
Stock solutions (10jAM) of DOX, ACM and ACM
metabolites (Laboratoires Roger Bellon, Paris, France) were
prepared in Dulbecco's PBS (pH = 7.4, ionic strength
I = 0.152 M, with 1 mM EDTA). Drug concentrations in PBS
solution were determined by their absorbances at 480 nm for
DOX and at 430 nm for ACM. Calf thymus DNA (Sigma
Chemical Company, type I) was dissolved in Dulbecco's PBS.
Concentration of DNA (phosphate) was estimated on the
basis of a molar absorption coefficient e = 6600 M-' cm ' at
260 nm. For in vitro studies, the appropriate amounts of
drugs were added to DMEM (Gibco), supplemented with
10% fetal calf serum (Seromed) and 2 mM L-glutamine.
Cells
K562 is a human leukaemia cell line, established from a
patient with chronic myelogeneous leukaemia in blast trans-
formation (Lozzio & Lozzio, 1975). K562 cells were kept in
exponential growth at 5-8 x 105 in DMEM supplemented as
described above. K562 cells resistant to DOX (K562-DOX)
were obtained by continuous exposure to increasing DOX
concentrations, and were maintained in DMEM containing
DOX (100nM). This subline expresses a unique membrane
glycoprotein with a molecular weight of 180,000 and pos-
sesses double minute chromosomes and homogeneously
staining regions which are supposed to contain amplified
DNA sequences responsible for multidrug resistance (Tsuruo
et al., 1986; Sugimoto & Tsuruo, 1987). Cell growth and
viability were determined by phase contrast microscopy with
0.1% Trypan Blue.
In drug uptake studies, cells in exponential growth phase
were incubated at 5 x 104ml1' density in DMEM containing
the appropriate drug concentration, using 24-well multidishes
in a moist air/CO2 incubator at 37°C. Cells were then washed
free of drug and seeded on a Petri dish containing PBS for
the microspectrofluorometric analysis. Routine measurements
of the fluorescence of 20 nuclei in each sample were made.
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Inhibition ofcell growth
Growth inhibition (GI) was determined as follows. Cells in
exponential growth phase at 5 x I04ml-' density were
incubated for 4 h in the medium containing the appropriate
amount of drugs. Cells were then washed and resuspended in
drug-free medium. After 3 days, triplicate cell counting was
performed by phase contrast microscopy. Cell growth was
estimated as doubling number per 24 h, Nd, according to
equation (1) for cells in exponential phase, were N, and N2
are cell concentrations at times T, and T2, i.e.
N2= N,-2Nd(T2 -T1) (1)
Inhibition of cell growth was calculated as a ratio between
doubling number of treated cells and doubling number of
untreated cells. G120 for example, is defined as the drug
concentration which reduces to 20% the doubling number
(Nd) of treated cells in comparison to control.
The microspectrofluorometer
Fluorescence emission spectra from a microvolume within a
living cell were recorded with a microspectrofluorometer
(modified Raman spectrometer OMARS 89, DILOR, Lille,
France) as described previously (Ginot et al., 1984; Gigli et
al., 1988; Millot et al., 1989).
An optical microscope (Olympus BH2) equipped with a
100 x water immersion objective (Leitz Fluotar) and phase
contrast allows us to: (i) observe the sample; (ii) focus a laser
beam at 457.9 nm (Spectra Physics Ar+ 2020/03) on a spot of
1 ltm diameter; and (iii) collect the fluorescence emission
through the same optics. The fluorescence sampling was
restricted to a volume of about 30ym3 with a pinhole dia-
phragm of 200 lum diameter on the image plane of the micro-
scope objective. An interference filter (MTO J480) is used to
decrease the scattered light intensity from the excitation line
by 10'2-fold. The emitted light signal, spectrally dispersed by
a diffraction grating, was detected with an optical multichan-
nel analyser consisting of a cooled 512 element diode array,
optically coupled with an image intensifier. Data were trans-
ferred to a Goupil G4 computer for analysis with the
specifically developed program Spectre.
Microspectrofluorometric measurements
For the microspectrofluorometric analysis, the cells were
incubated in the medium containing DOX and ACM. Then
they were washed free of drug in cooled PBS at 4°C and
seeded in a Petri dish containing PBS. These survival condi-
tions without glucose decrease the energy metabolism and the
active outward transport of resistant cells. By repeated
measurements at 37°C, at regular intervals for more than 1 h,
on the same location on a single cell nucleus, a decrease of
intranuclear DOX concentration could also be detected for
K562 and K562-DOX cell lines. The results of the above
measurements are represented by the following equation:
C = CO x (1-t x 0.003)
Where C is the intranuclear DOX concentration depending
on time t, which is expressed in minutes.
All data reported in this work have been collected from a
sample of 20-30 different cell nuclei within the first 15 min
after transferring cells in PBS. Under these experimental
conditions, the intranuclear concentrations remained essen-
tially unaffected (of the order of 5%) during the total time
interval within these limits. Twenty spectra from the same
intracellular location were accumulated in order to increase
the signal to noise ratio. Sample heating and photobleaching
were found to be negligible under our experimental condi-
tions. A light power of 4yW at the sample and an illumina-
tion time of 1 s were used. Cells always remained viable after
repeated fluorescence measurements as determined by phase
contrast microscopy. Spectra were numerically corrected for
the photodiode array response due to small differences in the
quantum yield of each diode and for the transmission of the
interference filter.
Laser power and instrumental response were controlled by
the daily use of rhodamine B (C= 70 nM in ethyl alcohol
solution) as an external standard.
Determination ofthe DOX concentration in living cell nuclei
The fluorescence signal at a given wavelength, arising from
the nucleus of a cell treated with DOX F(A), can be expressed
as a sum of spectral contributions of free DOX, DNA-bound
DOX and an intrinsic nuclear signal, i.e.
F(1) = Cf.FKQ) + Cb.Fb(Q) + cx.Fn(Q) (2)
Where Ff and Fb are the fluorescence spectra of free and
bound drug referred to unitary concentration. Taking into
account the unitary concentration, Cf and Cb represent int-
ranuclear concentrations of free and bound drug respectively.
ai is the contribution of a fictitious intranuclear component
responsible for the intrinsic nuclear spectrum F,. In a recent
paper (Gigli et al., 1988), we have shown that each of these
contributions has a characteristic spectral shape determined
independently by studies of aqueous solutions. Reference
spectra, corrected for buffer contribution, for free DOX
(0.12 tM) (Ff) in PBS solution and DOX (2pM) bound to
DNA (concentration in phosphate: 1 mM) in PBS (Fb) are
presented in Figure 1, after normalisation of the integrated
surfaces. The fluorescence yield of DOX in the free form is
higher than that of the bound form by a factor 48±2.
For simultaneous incubation with ACM and DOX, the
intranuclear spectral analysis must take into account two
additional contributions derived from the following com-
pounds: (i) ACM; and (ii) 7-deoxyaklavinone, termed C,.
The fluorescence yield of free ACM (5 x 10- M) is 200 times
higher compared to the ACM (5 x 10- M) bound to DNA
(1 mM) (Manfait et al., 1988). C,, one intracellular metabolite
from ACM with an altered chromophore, results from an
enzymatic cleavage of the trisaccharide and has been isolated
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Figure 1 Fluorescence emission spectra, corrected for the buffer
contribution, of anthracyclines in PBS solution. Free DOX
(0.12 uM) (A), DOX (2ILM) bound to DNA (1 mM) (0), after
normalisation of the integrated surfaces. Ratio between
fluorescence yield of DOX bound to DNA and free DOX: 1/48.
Free ACM (0.5 IiM) (*), C, (0.5fiM) (-). Laser excitation
wavelength: A = 457.9 nm, laser power at the sample: 4ItW.680 J.-M. MILLOT et al.
and identified by HPLC (Ogasawara et al., 1981; Egorin et
al., 1982) and microspectrofluorometric studies. Thus, equa-
tion (2) becomes:
F(A) = Cf.Ff (A) + Cb.Fb(A) + 1x.F,(A) + P.Fa(I) + y.FC(A) (3)
Where Fa and F, are fluorescence spectra of ACM and Cl
(Figure 1). P and A are their surface contributions in the
intranuclear spectrum F(1) of a K562 cell after exposure to
ACM and DOX. Using the resolution of the diode array
detector, equation (3) corresponds to a system of 512 equa-
tions, which are solved by minimisation of term 4 with a
least squares algorithm, and leads to DOX concentrations in
the living cell nucleus (Cf, Cb).
700 nm
Z [F(A) - (Cf.Ff&A) + Cb.Fb(A) +,.F.(A) +P.Fa(A) +y-.F(A))J2 (4)
A= 500
A fluorescence emission spectrum, as determined from a
selected microvolume in the nucleus of a K562 cell after a
simultaneous exposure with ACM and DOX, is shown in
Figure 2. The resolution into five components (free DOX,
bound - DNA DOX, ACM, C, and the intrinsic nuclear
contribution), leading to the computed DOX concentration,
is also shown in Figure 2. Notice that the free DOX con-
tributes about one-quarter of the total DOX signal, although
this species only constitutes 0.2% of the total drug concent-
ration. This result is general for K562 and K562-DOX cell
lines and for the investigated range of drug concentrations in
the medium (Gigli et al., 1989).
Results
Effect ofACM on DOX-induced growth inhibition in sensitive
and resistant K562 cells
The growth inhibition following 4 h exposure to ACM or
DOX was determined as reported in the Materials and
methods section. Table I shows the growth inhibitory activity
of ACM and DOX on K562 and K562-DOX cells. K562-
DOX cells, selected for 25-fold resistance to DOX, were
7-fold resistant to ACM, when compared with the GI50 of
both cell lines.
To detect a synergy mechanism between ACM and DOX
on cellular toxicity, cells were incubated for 4h in DOX
without and with non-toxic ACM concentrations (growth
inhibition < 5%): 10nM for K562, 50nM for K562-DOX.
Growth of both cell lines was evaluated by their cellular
doubling number. Cytotoxic effects of each incubation pro-
cess are compared in Figure 3. For the K562 line, simul-
taneous incubation with DOX and a non-toxic ACM dose
(10 nM) did not produce any enhancement of the DOX
cytotoxicity. On the contrary, for the resistant line, incuba-
tions with DOX and a non-toxic ACM dose (50nM) pro-
moted a partial restoration of the DOX activity. For exam-
ple, DOX (2,000 nM) associated with ACM (50 nM) gives a
similar toxicity to DOX (3,000 nM) alone. In this case, ACM
(50 nM) allows a DOX dose decrease of 33%, which corres-
ponds to a partial reversal of anthracycline resistance.
K562-DOX cells have been exposed to ACM and DOX,
according to two different associations in order to compare
their cytotoxic activity: (i) simultaneous exposures with ACM
and DOX and (ii) ACM pretreatments followed by DOX
alone (Figure 4). For each incubation process, the concentra-
tion ratio ACM/DOX = 1, and the exposure time to each
drug is 1 h. Compared to the ACM pretreatments, simul-
taneous exposures to both anthracyclines produced higher
cell growth inhibitions. This observation became more evi-
dent for ACM and DOX doses superior to I tIM.
A synergistic effect between DOX and ACM against K562-
DOX cells can be justified on the basis ofdeviations from the
expected additive cytotoxicity determined with each drug
used alone and represented by an isobologram (Steel et al.,
1979). Since the dose-response curves of ACM and DOX are
non-linear, the expected additive GI50 of K562-DOX cells is
represented on an isobologram as shown in Figure 5, corres-
ponding to 4 and 1 h exposure time respectively. This
isoeffect plot is defined from the ACM and DOX doses that
give growth inhibitory values that add up to the level GI50.
The addition is performed by taking the increments in DOX
doses starting from zero for calculation by mode I, and from
the GIso for calculation by mode II (Steel et al., 1979). The
datum from Figure 3 corresponding to an exposure of K562-
DOX cells to DOX (1,500 nM) and ACM (50 nM)(GI5o at
4 h) has been reported on the isobologram (Figure 5a). This
point appears on the left of the envelope of additivity and
could be interpreted in terms of a cytotoxic potentiation
mechanism between ACM and DOX against K562-DOX
cells. The point from Figure 4 corresponding to a simul-
taneous exposure with DOX (1,000 nM) and ACM
(1,000 nM) (GI50 at 1 h) is reported in Figure Sb and confirms
this conclusion. In contrast the point from Figure 4 corres-
ponding to a sequential exposure with ACM (3,000 nM) fol-
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Figure 2 Analysis of the emission spectrum from a microvolume
within the nucleus of a K562 cell exposed 2 h to I LM DOX and
I tLM ACM. The experimental spectrum (A) is resolved, using the
minimisation of term 4 reported in the Material and methods
section, into five contributions derived from these compounds:
free DOX (A), DNA-bound DOX (A), free ACM (*), C, (-)
and an untreated cell nucleus (0). The corrected fluorescence
emission spectrum of DOX from a treated cell nucleus is the
spectrum (0). Total intranuclear concentration of DOX,
evaluated from equation (3), is 82±8 iM. Conditions of laser
excitation as in Figure 1.
Table I Growth inhibitory concentration (GI) of DOX and ACM in
K562 and K562-DOX cells
DOX ACM
K562 K562-DOX K562 K562-DOX
G120 (nM) 50 1000 20 180
G150 (nM) 80 2100 65 450
GIoo (nM) 200 5000 800 1400
Growth inhibition was determined on cells exposed for4 h to a given
drug concentration, and resuspended for 3 days in drug-free medium.
Growth inhibition was calculated as per cent ratio between doubling
numberoftreated cellsanddoubling numberofuntreatedcells. Growth
inhibitoryconcentrationswerecalculatedfrom threetofiveindependent
determinations. Each standard deviation was less than 15% of the
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Figure 3 Growth inhibitory effect of doxorubicin on K562 and
K562-DOX cells, without and with aclacinomycin A. Cells were
simultaneously exposed to both drugs for 4 h at 37'C,
resuspended for 3 days in drug-free medium and then counted.
(0) K562 (OnM ACM); (-) K562 (lOnM ACM); (0) K562-
DOX (0 nM ACM); (-) K562-DOX (50 nM ACM). Growth
inhibitory effect was calculated as in Table I. Each point
represents the mean and each bar the standard deviation of three
experiments. Observed differences in growth inhibitions of K562-
DOX cells (,O) are significant: P<0.001.
ACM doses (>M)
ACM doses (>M)
Figure 5 Isobolograms (or isoeffect plots) of G150 against K562-
DOX cells with ACM-DOX associations. The expected additive
G150 are represented with calculations by mode I (-) and by
mode II (0) as defined by Steel et al. (1979). a, Cells were
exposed for 4 h to each drug; (0) is a projection from Figure 3
of ACM-DXR simultaneous incubation that gives GI50. b, Cells
were exposed for I h to each drug; (x) and (0) are projections
from Figure 4 of simultaneous and sequential incubations respec-
tively that give G150-
lowed by DOX (3,000 nM) (GI50 at 1 h) gives a point that lies
within the envelope of additivity.
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Figure 4 Comparison of drug associations (ACM and DOX), on
the growth inhibition of K562-DOX cells. (O) Cells were exposed
simultaneously to both drugs for I h; (0) cells were pre-treated
for I h with ACM, washed and resuspended for I h in ACM-free
medium containing DOX. Cells were washed and after 3 days in
drug-free medium, growth inhibitory effects were calculated.
Drug concentration ratio ACM/DOX = 1. Each point represents
the mean and each bar the standard deviation of three
experiments.
Effect ofACM on the intranuclear DOX uptake
A previous study reported that DOX cytotoxicity was depen-
dent on the drug concentration in nuclei and that the resis-
tant K562 subline exhibited an altered DOX uptake (Gigli et
al., 1989). To determine whether co-incubation with ACM
produces an enhancement of DOX intranuclear concentra-
tion, we have measured intranuclear concentrations of DOX
by microspectrofluorometry, as a function of extracellular
doses of ACM. This relationship is shown in Figure 6. For
K562-DOX cells, after 4 h of incubation with ACM and
DOX (1 JAM), DOX intranuclear concentrations were in-
creased proportionally to ACM extracellular doses. In con-
trast, for the sensitive line, the DOX uptake into the nucleus
was found to be independent of the ACM dose in the
medium.
The time-course of DOX intranuclear uptake and the effect
of ACM (1 JAM) on this process is shown in Figure 7. The
rate of DOX accumulation in the parent line is not
influenced by the presence of ACM. In resistant cells, the
intranuclear concentration of DOX is increased 5-fold with
the presence of ACM (1 ILM). During the first hour, this
uptake is similar to the one of sensitive cells, but afterwards
the DOX uptake reaches a maximum, contrary to the sen-
sitive cells.
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Effect ofACM on the intranuclear DOX retention
It has been shown repeatedly that calcium antagonists and
calmodulin inhibitors stimulate drug accumulation in resis-
tant cells by inhibition of the drug efflux. The intranuclear
retention of DOX from preloaded cells, determined by mic-
rospectrofluorometry, is shown in Figure 8. When CO is the
initial intranuclear DOX concentration ofpreloaded cells, the
DOX concentration (C) retained inside the nucleus in the
presence of DOX-free medium is described by an exponential
decrease:
C = Co. 10--log2/Tj/2
Where t is time and T1/2 is the time corresponding to
decrease of the intranuclear DOX concentration. DO)
from resistant cells (T1/2= 30 min) occurs faster tha
from sensitive cells (T1/2 = 8 h). The presence of ACM
during the DOX efflux phase increased the DOX rel
from K562-DOX cell nuclei (T1/2 =90 min), but did no'
the efflux from the nuclei of sensitive cells.
A more detailed study of DOX uptake and retenti4
explain the weaker efficiency of sequential exposures to
followed by DOX, compared to simultaneous exposi
both drugs, which have been reported in the Effect of
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Figure 6 DOX uptake in the nucleus of K562 (0) and I
DOX (O) cells, as a function of extracellular concentratic
ACM. Cells were exposed simultaneously to DOX (IpiM ACM. After 4 h, intranuclear concentrations of DOX were
mined. Vertical bars denote standard deviations on the
nuclear DOX concentration values, as determined froi
measurements.
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Figure 8 Effect of ACM on the DOX retention from nuclei of
K562 and K562-DOX cells. Cells were exposed to DOX (K562,
0.5 jIM; K562-DOX, 5lM) for I h at 37°C. Initial intranuclear
concentrations of DOX were 83 ± 1311M and 49± 11 jiM for
K562 and K562-DOX respectively. Cells were washed with PBS
and resuspended in DOX-free medium, without and with ACM
(I1jM). (0) K562 (OjgM ACM); (A) K562 (I jM ACM); (-)
K562-DOX (OIM ACM); (A) K562-DOX (I jiM ACM). Each
point represents the mean of three replicates with 30 cell nuclei.
The results are given with an accuracy of 10%. Data were fitted
to equation (5) with the following T,/2: (0) 8 h; (A) 8 h; (O)
30min; (A) 90 min.
on DOX-induced growth inhibition section. DOX uptakes in
resistant cell nuclei are compared in Figure 9, as a function
of the time, according to the type of incubation with
associated DOX and ACM. DOX was permanently present
in the medium, but ACM was added with various delays.
The similarity of curves (O) and (*) shows that a pretreat-
ment with ACM does not influence the intranuclear DOX
uptake. A comparison of curves (U) and (A) shows that a
removal of ACM from the extracellular medium induces a
fast DOX efflux out of the nucleus. Within 30 min the
04 intranuclear DOX concentration has decreased by 50%,
corresponding to the initial T,/2 value (30min) of resistant
cells without ACM. However, the inhibition of DOX efflux
K562- by ACM is reversible and requires the permanent presence of
)ns of ACM in the medium.
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Figure 7 Effect of ACM on the DOX up
K562-DOX cell nuclei, as a function of th
exposed to DOX (1 giM), without and with
K562 (O0 IM ACM); (A) K562 (1 jiM ACM
(OgiM ACM); (A) K562-DOX (I jiM ACM).'
standard deviations on the intranuclear E
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Figure 9 Effects of sequential and simultaneous ACM-DOX
5 6 7 incubations, on the intranuclear uptake of DOX in K562-DOX
cells, as a function of the time. From time 0, K562-DOX cells
were exposed to DOX (I pM) at 37TC: (O) without ACM; (*)
)take in K562 and cells were pre-treated for I h with ACM (1 piM) alone, washed
ie time. Cells were and resuspended at time 0 in DOX (I piM) alone; (A) cells were
ACM (1 piM). (0) exposed for the first hour simultaneously to ACM (I jiM) with
[); (U) K562-DOX DOX, washed and resuspended in DOX alone; (-) cells were'
Vertical bars denote incubated for 4 h simultaneously with ACM (I piM) and DOX.
)OX concentration Vertical bars denote standard deviations on the intranuclear
s. DOX concentration values, as determined from 30 measurements.
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Discussion
To avoid failure of chemotherapeutic treatment due to the
emergence of drug resistance, attempts have been made to
circumvent this problem either by using new drugs partic-
ularly able to overcome anthracycline resistance, or by an
association of drugs where one agent increases the phar-
macological effects of the other. Several classes of drugs have
been shown to reverse acquired resistance to anthracycline,
including calcium channel blockers (verapamil) (Tsuruo et
al., 1983; Friche et al., 1987), calmodulin antagonists
(trifluoperazine, perhexilene maleate) (Ganapathi et al.,
1984), triparanol analogues (tamoxifen) (Ramu et al., 1984),
cardiac anti-arhythmics (quinidine, amiodarone) (Chauffert et
al., 1986; Tsuruo et al., 1984) and cyclosporins (Twentyman,
1988).
ACM, an antineoplasic agent (Umezawa et al., 1987), has
been shown to circumvent anthracycline resistance at the
high dose of 10pgml-l (Tapiero et al., 1988). Moreover, a
significant synergistic effect of cytotoxicity against P388
leukaemia has been observed with the associations
ACM-cyclophosphamide and ACM-vincristine (Fugimoto
et al., 1979). Compared with other drug combinations used
to reverse the resistance, the interest in ACM is because of its
own significant activity against a number of human tumours
and its current use in clinical investigations (Kumai et al.,
1984; Majima et al., 1987). Moreover, in vitro studies have
shown a slight cross-resistance between ACM and DOX
(Umezawa et al., 1987; Tapiero et al., 1988).
Any association of drugs is unable to restore the full
sensitivity of resistant cells in vivo. For example, even if, in
vitro, verapamil induces increased drug uptake in resistant
cells, in vivo experiments indicate that verapamil, at a
tolerated dose, can only partially overcome drug resistance
(Friche et al., 1987). This result is probably entirely due to
the toxicity limitation of dosage, which allows only a
insufficient plasma concentration of verapamil during the
DOX uptake phase. Since our principal aim was to reverse in
vitro drug resistance in incubation conditions close to in vivo
conditions, we have implemented short-term incubations with
ACM doses corresponding to plasma concentration from
1 ttM to 200 nM during the first hour after an i.v. bolus
(Egorin et al., 1982). These short-term incubations probably
reflect, better than continuous incubations, the in vivo plasma
conditions following a bolus injection. In these incubation
conditions, an ACM dose which alone does not produce any
growth inhibition on DOX resistant cells, does induce a
partial reversal of DOX resistance.
As for other agents that reverse r -sistance to DOX, the
possible mechanism of this synergistic effect could depend on
increased uptake of DOX induced by ACM in resistant cells.
The mechanism of DOX action has been attributed to inter-
calation with DNA (Manfait et al., 1982) with the result that
DNA replication and RNA synthesis is inhibited (Zunino et
at.,1980), strand-breaking of DNA by bioreductive alkylation
occurs (Moore, 1977) and oxygen-free radicals are generated
(Bachur et al., 1979). Although the relationship between the
cytotoxic effect of DOX with total cellular drug content is
unclear (Lane et al., 1987), we have shown previously a direct
relationship between the growth inhibition effect and the
DOX amount actually in the nucleus (Gigli et al., 1989). Our
findings suggest that there is an enhancement of DOX
cytotoxicity with increased intranuclear concentration of this
drug induced by ACM. The combined effect of these
independent observations strongly supports the hypothesis
that the nucleus is a target for DOX.
Three hypotheses could explain the increase of the amount
of intranuclear DOX caused by ACM: (i) an alteration of
DOX influx, (ii) an alteration of DOX efflux, or (iii) a
redistribution of DOX inside the cell, allowing it to reach
targets more conducive to cytotoxicity. In the light of data
implicating increased activity of a membrane-associated
pump called P-glycoprotein in acquired resistance, particular
attention was given to drug efflux out of the nucleus in our
system. With direct observation inside the nucleus of living
cells, using microspectrofluorometry, we show that DOX is
bound to DNA by a reversible interaction. The DOX efflux
from the nucleus occurs faster in K562-DOX cells compared
to sensitive cells, with the result that resistant cells are able to
reduce intranuclear DOX concentrations to sublethal values
by active efflux.
This study demonstrates that the presence of ACM blocks
the DOX efflux in the resistant cell line, resulting in enhanced
accumulation of DOX and increased cytotoxicity. Because of
the rapid accumulations of ACM into sensitive and multi-
drug resistant lines (Seeber et al., 1980; Tapiero et al., 1988),
the ACM intracellular deposition might in turn affect the
DOX efflux. In contrast, another agent (forskolin) which
reversed resistance to DOX, with increase of DOX cellular
amounts, has virtually no effect on the rate of drug efflux
(Wadler & Wiernik, 1988). The exact function of P-
glycoprotein is not well known; however, a recent study has
demonstrated drug binding to this protein (Cornwell et al.,
1986), suggesting its involvement in drug transport. So, the
altered efflux of DOX by ACM in resistant cells could result
from a molecular interaction between ACM and the P-
glycoprotein or from an altered expression of this protein.
In conclusion, our results indicate that ACM partly
reverses DOX-resistance at clinically achievable concentra-
tions. We find that the reversal of resistance induced by
ACM, associated with the DOX efflux inhibition, is reversible
and requires the continuous presence of ACM in the
medium. Thus, toxicologic, pharmacokinetic studies and
clinical trials as resistance modifiers are now in progress by
using the ACM-DOX association in simultaneous injections.
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